Chiral Kinase Inhibitors

Overview

Journal Curr Top Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2011 Feb 5

PMID 21291394

Citations 5

Authors

Jian-Kang Jiang

Min Shen

Craig J Thomas

Mathew B Boxer

Affiliations

Soon will be listed here.

Abstract

Small molecule kinase inhibitors are important tools for studying cellular signaling pathways, phenotypes and are, occasionally, useful clinical agents. With stereochemistry pervasive throughout the molecules of life it is no surprise that a single stereocenter can bestow a ligand with distinct binding affinities to various protein targets. While the majority of small molecule kinase inhibitors reported to date are achiral, a number of asymmetric compounds show great utility as tools for probing kinase-associated biomolecular events as well as promising therapeutic leads. The mechanism by which chirality is introduced varies but includes screening of chiral libraries, incorporation of chiral centers during optimization efforts and the rational installation of a chiral moiety as guided by structural and modeling efforts. Here we discuss several advanced chiral small molecule kinase inhibitors where stereochemistry plays an important role in terms of potency and selectivity.

Citing Articles

Stereochemical editing logic powered by the epimerization of unactivated tertiary stereocenters.

Zhang Y, Palani V, Seim A, Wang Y, Wang K, Wendlandt A Science. 2022; 378(6618):383-390.

PMID: 36302032 PMC: 9974169. DOI: 10.1126/science.add6852.

Identification of highly selective type II kinase inhibitors with chiral peptidomimetic tails.

Han S, Jung J, Oh D, Kim M, Kim J, Chung K J Enzyme Inhib Med Chem. 2022; 37(1):1257-1277.

PMID: 35484863 PMC: 9067983. DOI: 10.1080/14756366.2022.2068148.

Rapid Optimization of the Metabolic Stability of a Human Immunodeficiency Virus Type-1 Capsid Inhibitor Using a Multistep Computational Workflow.

Meuser M, Reddy P, Dick A, Maurancy J, Salvino J, Cocklin S J Med Chem. 2021; 64(7):3747-3766.

PMID: 33750123 PMC: 8043142. DOI: 10.1021/acs.jmedchem.0c01810.

Design, Synthesis and Biological Evaluation of Isoxazole-Based CK1 Inhibitors Modified with Chiral Pyrrolidine Scaffolds.

Luxenburger A, Schmidt D, Ianes C, Pichlo C, Kruger M, von Drathen T Molecules. 2019; 24(5).

PMID: 30832206 PMC: 6429214. DOI: 10.3390/molecules24050873.

Structural insights into FRS2α PTB domain recognition by neurotrophin receptor TrkB.

Zeng L, Kuti M, Mujtaba S, Zhou M Proteins. 2014; 82(7):1534-41.

PMID: 24470253 PMC: 4057350. DOI: 10.1002/prot.24523.

References

Natarajan S, Doherty J . P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes. Curr Top Med Chem. 2005; 5(10):987-1003. DOI: 10.2174/1568026054985876. View

Brancho D, Tanaka N, Jaeschke A, Ventura J, Kelkar N, Tanaka Y . Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 2003; 17(16):1969-78. PMC: 196252. DOI: 10.1101/gad.1107303. View

Pesu M, Laurence A, Kishore N, Zwillich S, Chan G, OShea J . Therapeutic targeting of Janus kinases. Immunol Rev. 2008; 223:132-42. PMC: 2634846. DOI: 10.1111/j.1600-065X.2008.00644.x. View

Yap T, Garrett M, Walton M, Raynaud F, de Bono J, Workman P . Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol. 2008; 8(4):393-412. DOI: 10.1016/j.coph.2008.08.004. View

Thress K, Macintyre T, Wang H, Whitston D, Liu Z, Hoffmann E . Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther. 2009; 8(7):1818-27. DOI: 10.1158/1535-7163.MCT-09-0036. View

Jackson P, Bullington J . Pyridinylimidazole based p38 MAP kinase inhibitors. Curr Top Med Chem. 2002; 2(9):1011-20. DOI: 10.2174/1568026023393372. View

Lin X, Murray J, Rico A, Wang M, Chu D, Zhou Y . Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies. Bioorg Med Chem Lett. 2006; 16(16):4163-8. DOI: 10.1016/j.bmcl.2006.05.092. View

Smalley K . A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int J Cancer. 2003; 104(5):527-32. DOI: 10.1002/ijc.10978. View

Zdychova J, Komers R . Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. Physiol Res. 2005; 54(1):1-16. DOI: 10.33549/physiolres.930582. View

10.

Bilodeau M, Balitza A, Hoffman J, Manley P, Barnett S, Defeo-Jones D . Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg Med Chem Lett. 2008; 18(11):3178-82. DOI: 10.1016/j.bmcl.2008.04.074. View

11.

Sebolt-Leopold J, Herrera R . Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004; 4(12):937-47. DOI: 10.1038/nrc1503. View

12.

Kunz H . Emil Fischer--unequalled classicist, master of organic chemistry research, and inspired trailblazer of biological chemistry. Angew Chem Int Ed Engl. 2002; 41(23):4439-51. DOI: 10.1002/1521-3773(20021202)41:23<4439::AID-ANIE4439>3.0.CO;2-6. View

13.

Defeo-Jones D, Barnett S, Fu S, Hancock P, Haskell K, Leander K . Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther. 2005; 4(2):271-9. View

14.

Aronov A, Baker C, Bemis G, Cao J, Chen G, Ford P . Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. J Med Chem. 2007; 50(6):1280-7. DOI: 10.1021/jm061381f. View

15.

Williams N, Bamert R, Patel O, Wang C, Walden P, Wilks A . Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol. 2009; 387(1):219-32. DOI: 10.1016/j.jmb.2009.01.041. View

16.

Cho H, Mu J, Kim J, Thorvaldsen J, Chu Q, Crenshaw 3rd E . Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001; 292(5522):1728-31. DOI: 10.1126/science.292.5522.1728. View

17.

Yoeli-Lerner M, Toker A . Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle. 2006; 5(6):603-5. DOI: 10.4161/cc.5.6.2561. View

18.

Nakagawara A . Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001; 169(2):107-14. DOI: 10.1016/s0304-3835(01)00530-4. View

19.

Lad S, Neet K, Mufson E . Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. Curr Drug Targets CNS Neurol Disord. 2003; 2(5):315-34. DOI: 10.2174/1568007033482724. View

20.

Schett G, Zwerina J, Firestein G . The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis. 2007; 67(7):909-16. PMC: 2754165. DOI: 10.1136/ard.2007.074278. View